| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 9.7% | +16% | $90,358,800 | +$13,440,000 | 10,757,000 | +17% | Dapice Joshua J. | 30 Sep 2025 |
| EcoR1 Capital, LLC | 9.9% | $13,501,035 | 10,630,736 | EcoR1 Capital, LLC | 31 Dec 2024 | |||
| TCG Crossover GP II, LLC | 6.3% | $71,704,046 | 8,536,196 | TCG Crossover GP II, LLC | 30 Sep 2025 | |||
| Third Rock Ventures IV, L.P. | 5.8% | -16% | $62,760,355 | -$11,955,000 | 7,874,574 | -16% | Third Rock Ventures IV, L.P. | 19 Nov 2025 |
| Woodline Partners LP | 5.6% | $41,606,351 | 6,029,906 | Woodline Partners LP | 30 Jun 2025 | |||
| Invus Global Management, LLC | 5.3% | $40,593,997 | 5,883,188 | Raymond Debbane | 19 Sep 2025 | |||
| BlackRock, Inc. | 5% | $6,221,014 | 5,457,030 | BlackRock, Inc. | 30 Jun 2025 | |||
| Adage Capital Management, L.P. | 2.3% | -64% | $21,092,400 | -$28,512,532 | 2,511,000 | -57% | Adage Capital Management, L.P. | 30 Sep 2025 |
| FMR LLC | 0% | $17,008 | 13,392 | FMR LLC | 29 Nov 2024 |
As of 30 Sep 2025, 141 institutional investors reported holding 139,978,941 shares of Tango Therapeutics, Inc. - Common Stock (TNGX). This represents 104% of the company’s total 134,608,103 outstanding shares.
The largest institutional shareholders of Tango Therapeutics, Inc. - Common Stock (TNGX) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TRV GP IV, LLC | 10% | 13,863,975 | -18% | 43% | $116,457,390 |
| FARALLON CAPITAL MANAGEMENT LLC | 8% | 10,757,000 | +17% | 0.51% | $90,358,800 |
| EcoR1 Capital, LLC | 7.9% | 10,630,736 | 0% | 4.3% | $89,298,182 |
| Boxer Capital Management, LLC | 7.3% | 9,771,485 | 0% | 26% | $82,080,474 |
| TCG Crossover Management, LLC | 6.3% | 8,536,196 | -20% | 3.5% | $71,704,046 |
| Woodline Partners LP | 4.5% | 6,029,928 | +0% | 0.24% | $50,651,395 |
| Siren, L.L.C. | 4.4% | 5,883,188 | +75% | 1.9% | $49,418,779 |
| BlackRock, Inc. | 4.2% | 5,646,919 | +3.4% | 0% | $47,434,120 |
| Nextech Invest, Ltd. | 4.1% | 5,533,980 | 0% | 7.1% | $46,485,432 |
| VANGUARD GROUP INC | 3.8% | 5,052,003 | +25% | 0% | $42,436,826 |
| GILEAD SCIENCES, INC. | 3.6% | 4,854,443 | 0% | 2.3% | $40,777,321 |
| T. Rowe Price Investment Management, Inc. | 2.6% | 3,526,359 | +11% | 0.02% | $29,622,000 |
| Balyasny Asset Management L.P. | 2.6% | 3,472,207 | +6.9% | 0.06% | $29,166,539 |
| STATE STREET CORP | 2.5% | 3,365,205 | +143% | 0% | $28,267,722 |
| Paradigm Biocapital Advisors LP | 2.3% | 3,086,184 | 0.77% | $25,923,946 | |
| Point72 Asset Management, L.P. | 2.2% | 2,919,450 | 0.05% | $24,523,378 | |
| Bain Capital Life Sciences Investors, LLC | 2% | 2,712,008 | 0% | 1.5% | $22,780,867 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.9% | 2,511,000 | -57% | 0.03% | $21,092,400 |
| JANUS HENDERSON GROUP PLC | 1.7% | 2,302,274 | 0.01% | $19,316,079 | |
| RA CAPITAL MANAGEMENT, L.P. | 1.5% | 2,000,000 | 0% | 0.21% | $16,800,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,882,777 | +6.4% | 0% | $15,818,136 |
| Nantahala Capital Management, LLC | 1.3% | 1,809,948 | -47% | 0.94% | $15,203,563 |
| GOLDMAN SACHS GROUP INC | 1.1% | 1,509,475 | +1295% | 0% | $12,679,590 |
| Commodore Capital LP | 1.1% | 1,500,000 | 0% | 0.62% | $12,600,000 |
| MARSHALL WACE, LLP | 1.1% | 1,489,518 | -15% | 0.01% | $12,511,951 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 257,111 | $2,278,030 | +$252,776 | $8.86 | 3 |
| 2025 Q3 | 139,978,941 | $1,175,803,271 | +$109,407,073 | $8.40 | 141 |
| 2025 Q2 | 127,256,008 | $651,746,300 | +$113,427,500 | $5.12 | 115 |
| 2025 Q1 | 107,228,944 | $146,966,286 | -$1,500,597 | $1.37 | 119 |
| 2024 Q4 | 106,381,203 | $328,720,923 | -$120,602,121 | $3.09 | 134 |
| 2024 Q3 | 101,459,260 | $781,203,453 | -$3,585,028 | $7.70 | 119 |
| 2024 Q2 | 98,598,435 | $845,923,945 | +$2,706,235 | $8.58 | 116 |
| 2024 Q1 | 98,368,235 | $781,032,501 | +$30,588,350 | $7.94 | 123 |
| 2023 Q4 | 18,449 | $182,645 | +$3,990 | $9.90 | 1 |
| 2023 Q3 | 88,799,639 | $999,862,438 | +$237,330,948 | $11.26 | 99 |
| 2023 Q2 | 68,300,832 | $226,779,006 | -$7,767,598 | $3.32 | 88 |
| 2023 Q1 | 69,825,888 | $275,807,854 | +$1,727,684 | $3.95 | 90 |
| 2022 Q4 | 68,748,702 | $498,429,197 | +$12,867,744 | $7.25 | 82 |
| 2022 Q3 | 68,140,346 | $246,666,576 | -$11,889,002 | $3.62 | 85 |
| 2022 Q2 | 70,433,709 | $319,054,805 | -$11,306,482 | $4.53 | 75 |
| 2022 Q1 | 69,654,865 | $527,984,476 | +$13,372,743 | $7.58 | 69 |
| 2021 Q4 | 67,742,664 | $740,640,532 | +$24,563,447 | $10.94 | 56 |
| 2021 Q3 | 65,465,348 | $844,863,000 | +$844,863,243 | $12.93 | 45 |